Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tasigna® (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT00844298 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT00844298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00844298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tasigna® (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
July 31, 2014
Enrollment
91 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia